Observes outcomes in people with relapsed or refractory acute myeloid leukemia
Follows people with acute myeloid leukemia that has returned or not responded to treatment.
Plain-language title generated from the registry record
Registry title: Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Key facts
- Where
- Kaunas, LithuaniaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for people with acute myeloid leukemia (AML) whose treatment has failed: the leukemia came back, did not respond, or got worse. It only collects data on treatment outcomes.
- Age
- 6 Years and older
- Sex
- All sexes can join.
- Disease stage
- AML diagnosed by WHO2022 or ICC2022 criteria, with treatment failure (relapse, refractory disease or progression, including MRD) by ELN2022 criteria.
Main reasons for not taking part
- People already in other clinical trials can usually join, unless that trial's own protocol says otherwise.
Read by machine on 9 November 2026.
Where in Lithuania
- The Hospital of Lithuanian University of Health Sciences Kauno KlinikosKaunas, LithuaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Trial code
- NCT06459024
- Record updated
- 27 October 2026
- Original description
This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia afferent to the participanting clinical sitesRead full original descriptionShow less
Master Framework For Relapse or Refractory Acute Myeloid Leukemia- IMPACT STREAM - A Prospective Observational Study of Treatment Outcomes
This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia afferent to the participanting clinical sites
Inclusion: Patients with AML diagnosis according to WHO2022 or ICC2022; Treatment failure (i.e. relapse, refractory or progression, including MRD) according to ELN2022 criteria; Participant or his/her legal representative is willing and able to give informed consent for participation in the study.
Exclusion: Patients included in clinical trials may be enrolled except where otherwise specified in the experimental protocol.